1. Home
  2. RYTM vs WSC Comparison

RYTM vs WSC Comparison

Compare RYTM & WSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rhythm Pharmaceuticals Inc.

RYTM

Rhythm Pharmaceuticals Inc.

HOLD

Current Price

$102.60

Market Cap

5.8B

Sector

Health Care

ML Signal

HOLD

Logo WillScot Mobile Mini Holdings Corp.

WSC

WillScot Mobile Mini Holdings Corp.

HOLD

Current Price

$26.52

Market Cap

5.3B

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
RYTM
WSC
Founded
2008
1944
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Misc Corporate Leasing Services
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
5.8B
5.3B
IPO Year
2017
2015

Fundamental Metrics

Financial Performance
Metric
RYTM
WSC
Price
$102.60
$26.52
Analyst Decision
Strong Buy
Buy
Analyst Count
14
8
Target Price
$131.14
$24.14
AVG Volume (30 Days)
646.7K
1.8M
Earning Date
05-05-2026
05-07-2026
Dividend Yield
N/A
1.27%
EPS Growth
28.34
N/A
EPS
N/A
0.15
Revenue
N/A
$2,281,446,000.00
Revenue This Year
$55.34
N/A
Revenue Next Year
$86.06
$3.31
P/E Ratio
N/A
$179.20
Revenue Growth
N/A
N/A
52 Week Low
$74.50
$14.91
52 Week High
$122.20
$31.88

Technical Indicators

Market Signals
Indicator
RYTM
WSC
Relative Strength Index (RSI) 46.08 48.47
Support Level $98.30 $24.92
Resistance Level $113.51 $28.76
Average True Range (ATR) 3.76 0.98
MACD -1.65 -0.07
Stochastic Oscillator 11.09 50.00

Price Performance

Historical Comparison
RYTM
WSC

About RYTM Rhythm Pharmaceuticals Inc.

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.

About WSC WillScot Mobile Mini Holdings Corp.

WillScot Holdings Corp designs, delivers, and services on-site, on-demand space solutions for clients. The company offers turnkey solutions in construction, education, manufacturing, retail, healthcare, and entertainment sectors. The products of the company include modular office complexes, mobile offices, classrooms, blast-resistant modules, clearspan structures, sanitation solutions, portable storage containers, and climate-controlled containers and trailers.

Share on Social Networks: